116 related articles for article (PubMed ID: 38527071)
1. Incidence of oncogenic HPV infection in women with and without mental illness: A population-based cohort study in Sweden.
Herweijer E; Hu K; Wang J; Lu D; Sparén P; Adami HO; Valdimarsdóttir U; Sundström K; Fang F
PLoS Med; 2024 Mar; 21(3):e1004372. PubMed ID: 38527071
[TBL] [Abstract][Full Text] [Related]
2. Invasive cervical cancer, precancerous lesions, and cervical screening participation among women with mental illness in Sweden: a population-based observational study.
Hu K; Wang J; Sparén P; Herweijer E; Sjölander A; Adami HO; Valdimarsdóttir U; Sundström K; Fang F
Lancet Public Health; 2023 Apr; 8(4):e266-e275. PubMed ID: 36965981
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
5. Outcome and associated factors of high-risk human papillomavirus infection without cervical lesions.
Feng T; Cheng B; Sun W; Yang Y
BMC Womens Health; 2023 Nov; 23(1):599. PubMed ID: 37957634
[TBL] [Abstract][Full Text] [Related]
6. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
8. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
Castle PE; Solomon D; Schiffman M; Wheeler CM
J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
[TBL] [Abstract][Full Text] [Related]
10. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
11. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
12. High Prevalence of Cervical High-Grade Lesions and High-Risk Human Papillomavirus Infections in Women Living with HIV: A Case for Prioritizing Cervical Screening in This Vulnerable Group.
Gupta R; Hussain S; Hariprasad R; Dhanasekaran K; Verma S; Agarwal V; Sandeep ; Parveen S; Kaur A; Verma CP; Amita ; Dwivedi R; Singh S; Gupta S
Acta Cytol; 2022; 66(6):496-506. PubMed ID: 35760059
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.
Herweijer E; Feldman AL; Ploner A; Arnheim-Dahlström L; Uhnoo I; Netterlid E; Dillner J; Sparén P; Sundström K
PLoS One; 2015; 10(7):e0134185. PubMed ID: 26218492
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of oncogenic human papillomavirus (HPV 16/18) infection, cervical lesions and its associated factors among women aged 21-49 years in Amhara region, Northern Ethiopia.
Temesgen MM; Alemu T; Shiferaw B; Legesse S; Zeru T; Haile M; Gelanew T
PLoS One; 2021; 16(3):e0248949. PubMed ID: 33760866
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of oncogenic human papillomavirus infections and incident high-grade cervical intraepithelial neoplasia among smokers: experience from the Latin American screening study.
Sarian LO; Hammes LS; Longatto-Filho A; Guarisi R; Derchain SF; Roteli-Martins C; Naud P; Erzen M; Branca M; Tatti S; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
Sex Transm Dis; 2009 Apr; 36(4):241-8. PubMed ID: 19265732
[TBL] [Abstract][Full Text] [Related]
17. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
18. Impact of cervical screening by human papillomavirus genotype: Population-based estimations.
Wang J; Elfström KM; Lagheden C; Eklund C; Sundström K; Sparén P; Dillner J
PLoS Med; 2023 Oct; 20(10):e1004304. PubMed ID: 37889928
[TBL] [Abstract][Full Text] [Related]
19. [HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône].
Piana L; Leandri FX; Le Retraite L; Heid P; Tamalet C; Sancho-Garnier H
Bull Cancer; 2011 Jul; 98(7):723-31. PubMed ID: 21700548
[TBL] [Abstract][Full Text] [Related]
20. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
